Kurs
+5,00%
Kurs
+5,00%
Open
16,50
High
16,90
Low
16,20
Close
16,80
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Kalender
| Est. tid* | ||
| 2022-01-26 | - | Bokslutskommuniké 2021 |
| 2021-07-14 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-30 | - | Årsstämma |
| 2021-05-27 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-15 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-22 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
| 2020-06-19 | - | Årsstämma |
| 2020-05-06 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-19 | - | Bokslutskommuniké 2019 |
| 2019-11-13 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-31 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
| 2019-05-29 | - | Årsstämma |
| 2019-04-30 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-13 | - | Bokslutskommuniké 2018 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-31 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
| 2018-05-30 | - | Årsstämma |
| 2018-02-08 | - | Bokslutskommuniké 2017 |
| 2017-11-24 | - | Extra Bolagsstämma 2017 |
| 2017-08-16 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-16 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
| 2017-05-15 | - | Årsstämma |
| 2017-05-15 | - | Kapitalmarknadsdag 2017 |
| 2017-05-15 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-08 | - | Bokslutskommuniké 2016 |
| 2016-11-16 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-17 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-20 | - | Årsstämma |
| 2016-05-20 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-11-25 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2014-11-26 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-27 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-27 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-17 | - | Bokslutskommuniké 2013 |
| 2013-11-26 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-27 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-22 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-28 | - | Bokslutskommuniké 2012 |
| 2012-11-15 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-21 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-16 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-28 | - | Bokslutskommuniké 2011 |
| 2012-02-13 | - | Extra Bolagsstämma 2012 |
| 2011-11-17 | - | Kvartalsrapport 2011-Q3 |
| 2011-10-31 | - | Extra Bolagsstämma 2011 |
| 2011-08-18 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-19 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-25 | - | Bokslutskommuniké 2010 |
Beskrivning
| Land | Norge |
|---|---|
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2020-06-30 16:32:00
Oslo, Norway (30 June 2020)
At the Annual General Meeting ("AGM") today of Kaydence Pharma AS ("Kaydence
Pharma") it has been decided that NattoPharma ASA ("NattoPharma") will convert
NOK 4 million of its loans to equity in Kaydence Pharma. The loan will be
converted at NOK 5 per share giving NattoPharma a total number of 3 000 000
shares representing a 54.15% interest as at 30 June 2020. Following the
conversion, NattoPharma´s loan to Kaydence Pharma is NOK 51 million.
Further the AGM decided that the Board of Kaydence Pharma has been replaced with
Kjetil Ramsøy as Chairman of the Board and Robert Schrama as Director.
"The increase in ownership further secures NattoPharma's claim patents and is
therefore in line with our strategy", says Mr. Ramsøy. Erik Flatmark, the former
Chairman of Kaydence Pharma, says: "I am happy that NattoPharma has taken this
step in further securing control of Kaydence after the activities had been
suspended earlier this year."
Following these two decisions by the AGM, NattoPharma will have a controlling
interest and Kaydence Pharma will be part of the consolidated accounts of
NattoPharma going forward. The impact of the conversion will be reflected in the
Q2 financials.
***
For more information, please contact:
Robert Schrama, CFO
E-mail: robert.schrama@nattopharma.com
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities